Compare GKOS & PRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | PRIM |
|---|---|---|
| Founded | 1998 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.7B |
| IPO Year | 2015 | 2006 |
| Metric | GKOS | PRIM |
|---|---|---|
| Price | $126.04 | $98.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | $126.92 | ★ $155.20 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.19% |
| EPS Growth | N/A | ★ 51.66 |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $9.92 |
| Revenue Next Year | $27.43 | $8.80 |
| P/E Ratio | ★ N/A | $295.31 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $73.90 |
| 52 Week High | $148.11 | $205.50 |
| Indicator | GKOS | PRIM |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 35.56 |
| Support Level | $94.16 | N/A |
| Resistance Level | $147.43 | $133.04 |
| Average True Range (ATR) | 7.18 | 8.83 |
| MACD | 1.01 | -1.75 |
| Stochastic Oscillator | 91.26 | 23.38 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.